Developer docs
API playgroundTry for free, no card

Search company profiles

BioSerenity

Full company profile

uuid0000nz5

Namestring
BioSerenity
Legal namestring
BioSerenity Medical Devices Group
Websiteurl
bioserenity.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

BioSerenity is a French medtech company founded in 2014 that operates an integrated neuroscience platform combining connected medical devices, AI-powered signal analysis, and tele-interpretation services for neurology, sleep medicine, and cardiology. The core hardware consists of the Neuronaute+ portable EEG recorder and the IceCap disposable EEG cap system (five sizes from neonate to adult, up to 72-hour continuous recording), which connect via Wi-Fi to the Bioserenity Connect cloud platform for AI pre-analysis of signal abnormalities and remote specialist interpretation. AI capability is anchored by proprietary foundation models: the BIOSerenity-E1 self-supervised EEG model (arXiv, March 2025) and a multimodal sleep foundation model trained on 500,000+ hours of recordings (Nature Medicine, 2026) capable of predicting Parkinson's and breast cancer from sleep signals.

BioSerenity monetizes through three streams: sale of Neuronaute+ and IceCap devices to hospitals and clinics (hardware sales), 24/7 tele-interpretation services branded NeuroPhy (EEG), Somnophy (polysomnography), and Cardiophy (Holter ECG) delivered by a network of specialist physicians and technicians (professional services), and operation of dedicated sleep diagnostic centers inside customer healthcare facilities (managed services). Pricing is not publicly disclosed and is contracted on a B2B basis with healthcare providers. The company serves over 300 clinics and hospitals and a referral network of 9,000+ physicians, treating 150,000+ patients per year and performing 49,000+ EEGs in 2025.

The company holds FDA 510(k) clearances (four Class II devices), EU MDR Class IIa CE marking, ISO 13485:2016, and MDSAP certification covering US, Canada, Brazil, Japan, and Australia. Jolt Capital invested €24 million in November 2023 to fund US and broader European expansion and AI deployment, joining existing investors Bpifrance, Dassault Systemes, Idinvest Partners, LBO France, Kurma Partners, Scor, and Innovation Capital. Headquartered in Paris (relocated January 1, 2025), BioSerenity employs 251-500 people and operates with Emmanuel Mougeotte as CEO.

Short descriptiontext

BioSerenity is a French medtech company operating an integrated connected-EEG and tele-interpretation platform for hospitals and clinics, combining Neuronaute+ portable EEG recorders, IceCap disposable caps, AI-powered cloud analysis, and proprietary foundation models to serve neurology, sleep medicine, and cardiology diagnostics across 300+ facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
connected EEG devices, tele-interpretation services, sleep disorder diagnostics, neurology telemedicine, polysomnography interpretation
Industry4 codes
1Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
CodeHLAHACAEPrimaryYes
2Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
CodeHLACAPABPrimaryNo
3Neurology Telemedicine Platforms
CodeHLALAGACPrimaryNo
4Pulmonology & Sleep Medicine Telemedicine Platforms
CodeHLALAGAFPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurological Diagnostic Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Devices (Neuronaute+, IceCap)
TypeHardware Sales
Description

Sale and supply of connected EEG medical devices (Neuronaute+ portable EEG recorder and IceCap disposable EEG caps) to hospitals, clinics, and healthcare facilities. Devices are FDA and CE certified.

bioserenity.com
2Tele-Interpretation Services (NeuroPhy, Somnophy, Cardiophy)
TypeProfessional Services
Description

Remote diagnostic interpretation services for EEG (NeuroPhy), polysomnography (Somnophy), and ECG/Holter (Cardiophy). Services include on-demand realization and tele-interpretation by specialist doctors, available 24/7.

bioserenity.com
3Remote Diagnostic Centers
TypeManaged Services
Description

BioSerenity implements sleep diagnostic centers directly within healthcare facilities, providing a comprehensive service that combines equipment, technicians, and medical interpretation.

bioserenity.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 8 records shown
1Neurophy
Description

On-demand EEG realization and tele-interpretation service for hospitals and clinics.

bioserenity.com
+7 more records
Core offering1 text field

BioSerenity sells connected EEG medical devices (Neuronaute+ portable recorder and IceCap disposable caps) integrated with a cloud-based AI analysis platform and delivers round-the-clock tele-interpretation services for EEG, polysomnography, and Holter ECG to hospitals, clinics, and sleep medicine centers. The company combines hardware, AI software, and on-demand specialist physician interpretation to enable brain monitoring and remote diagnostics across neurology, sleep medicine, and cardiology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 150,000+ patients treated yearly through BioSerenity's diagnostic services
+6 more records
Product overview1 text field

BioSerenity is an integrated neuroscience platform comprising medical devices and telemedicine services. The core product portfolio includes Neuronaute+ (portable connected EEG recorder) and IceCap (disposable EEG caps) working together as a complete EEG system, supported by the Bioserenity Cloud platform for data storage and AI analysis. The service offerings include Neurophy (on-demand EEG tele-interpretation), Somnophy (polysomnography interpretation), and Cardiophy (Holter ECG interpretation), all delivered through a network of specialist physicians and technicians. B-Link and BLINK Mobile App are complementary accessories enabling video synchronization and mobile session configuration. The platform enhances neurological diagnostics and sleep disorder treatment through AI-powered pre-analysis of electrophysiological signals.

Product and service7 records
1Neuronaute+
CategoryMedical Device
Description

Portable and connected EEG recorder that enables electroencephalographic examinations at the patient's bedside, at home, or in complex hospital environments (ICU, pediatrics, operating rooms). Compact, battery-powered, lightweight device with interchangeable extensions compatible with IceCap and standard EEG caps. Features AI pre-analysis to screen signal abnormalities. FDA-cleared Class II (K231366) and CE-marked Class IIa medical device.

2IceCap
CategoryMedical Device
Description

Extra-light disposable EEG cap (less than 10 grams) available in 5 sizes from neonate to adult, set up in 10 minutes for hospital or home exams. Supports recordings up to 72 hours. Compatible with standard touchproof EEG acquisition systems via Neuronaute Touchproof adapters. CE-marked Class I and FDA-cleared Class II medical device.

3Bioserenity Cloud (Connect)
CategorySoftware Platform
Description

Web-based information system that receives EEG and video signals from the Neuronaute recorder and B-Link app through paired Wi-Fi connection. Enables long-term storage, signal integration, AI pre-analysis for abnormality screening, and remote analysis by specialists. Class IIa medical device.

4Neurophy
CategoryTelemedicine Service
Description

On-demand EEG realization and tele-interpretation service providing 24/7 technician deployment with Neuronaute+ and IceCap equipment to hospitals, clinics, and private practices. Average tele-interpretation time under 2 hours for routine EEG (maximum 3 hours) and 30 minutes for emergencies. Over 300 partner hospitals and 950+ weekly examinations performed in 2025.

5Somnophy
CategoryTelemedicine Service
Description

Remote polysomnography (PSG) interpretation platform providing realization and interpretation services for sleep studies. Network of sleep medicine physicians and technicians scoring PSG recordings from children to adults, 7 days a week, with 6-hour interpretation turnaround. 7 diagnostic sleep centers in France.

6Cardiophy
CategoryTelemedicine Service
Description

Remote Holter ECG interpretation service offering ECG monitoring with up to 14-day battery life, wireless 3-lead patch, and semi-waterproof design. Includes interpretation by cardiologist/electrophysiologist team. Service available with 24/7 technical support.

7B-Link Mobile Application
CategorySoftware Application
Description

Android application that transforms a smartphone into a video monitoring and recording station synchronized with EEG recordings. Sends video data to Bioserenity Cloud for remote specialist analysis. Class IIa medical device accessory.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

APTE Association is part of BioSerenity's Somnophy network of technicians holding Sleep Medicine degrees, providing pre-scoring services for polysomnography recordings.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Opossomm is part of BioSerenity's Somnophy network of technicians holding Sleep Medicine degrees, providing pre-scoring services for polysomnography recordings.

3Circle of Sleep Society
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Circle of Sleep Society is part of BioSerenity's Somnophy network of technicians holding Sleep Medicine degrees, providing pre-scoring services for polysomnography recordings.

bioserenity.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

BioSerenity collaborated with Ensodata to achieve a first-of-kind FDA clearance for interoperable AI analysis of PPG (photoplethysmography). Testimonial from Chris Fernandez, Executive Chairman and Chief Research Officer at Ensodata, highlights the successful collaboration.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Germany-based manufacturer of research- and clinical-grade EEG hardware and caps. Directly competes with Neuronaute+ and IceCap as a European EEG device specialist.

TypeDirect peer
Description

Australia-based manufacturer of clinical EEG, PSG, and sleep-diagnostic devices with cloud analysis software. Directly comparable to BioSerenity's hardware-plus-software stack for neurology and sleep labs worldwide.

TypeBroad incumbent
Description

Large neurology-diagnostics portfolio company offering EEG, PSG, EMG, and ICU monitoring devices globally. A broader incumbent that competes with BioSerenity's Neuronaute+ and IceCap in hospital neurology and sleep labs.

TypeDirect peer
Description

AI-powered point-of-care EEG system with cloud-based interpretation for hospital and ICU use. Closest analog to BioSerenity's combination of bedside EEG hardware + cloud AI + remote specialist interpretation.

TypeDirect peer
Description

Icelandic sleep-diagnostics company offering PSG systems and cloud software for sleep labs. Closely comparable to BioSerenity's Somnophy PSG interpretation offering and overall sleep franchise.

TypeDirect peer
Description

AI sleep-scoring and clinical diagnostics platform with FDA-cleared interoperable PSG analysis. BioSerenity has cited EnsoData as a collaborator on FDA-cleared PPG AI analysis — directly comparable on the AI-interpretation layer.

TypeEmerging player
Description

EEG-based personalized neurostimulation and brain-mapping platform. Comparable as an emerging EEG + AI + clinical-interpretation stack, though focused on therapy rather than diagnostics.

TypeEmerging player
Description

AI-driven EEG diagnostic platform for early detection of neurological conditions (e.g., Alzheimer's, depression). Comparable to BioSerenity's foundation-model strategy of using EEG for disease prediction.

TypeBroad incumbent
Description

Large patient-monitoring company whose SedLine EEG-processed brain-monitoring product overlaps with BioSerenity's hospital EEG franchise. A broad incumbent with global hospital-channel reach.

TypeBroad incumbent
Description

Global health-tech incumbent with sleep & respiratory (Philips Respironics) and clinical patient-monitoring portfolios. Overlaps with BioSerenity's Somnophy sleep-diagnostic and Cardiophy ECG services in hospital and home settings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSerenity

Neurological Diagnostic Servicesbioserenity.com

BioSerenity is a French medtech company operating an integrated connected-EEG and tele-interpretation platform for hospitals and clinics, combining Neuronaute+ portable EEG recorders, IceCap disposable caps, AI-powered cloud analysis, and proprietary foundation models to serve neurology, sleep medicine, and cardiology diagnostics across 300+ facilities.

What BioSerenity does

BioSerenity is a French medtech company founded in 2014 that operates an integrated neuroscience platform combining connected medical devices, AI-powered signal analysis, and tele-interpretation services for neurology, sleep medicine, and cardiology. The core hardware consists of the Neuronaute+ portable EEG recorder and the IceCap disposable EEG cap system (five sizes from neonate to adult, up to 72-hour continuous recording), which connect via Wi-Fi to the Bioserenity Connect cloud platform for AI pre-analysis of signal abnormalities and remote specialist interpretation. AI capability is anchored by proprietary foundation models: the BIOSerenity-E1 self-supervised EEG model (arXiv, March 2025) and a multimodal sleep foundation model trained on 500,000+ hours of recordings (Nature Medicine, 2026) capable of predicting Parkinson's and breast cancer from sleep signals.

BioSerenity monetizes through three streams: sale of Neuronaute+ and IceCap devices to hospitals and clinics (hardware sales), 24/7 tele-interpretation services branded NeuroPhy (EEG), Somnophy (polysomnography), and Cardiophy (Holter ECG) delivered by a network of specialist physicians and technicians (professional services), and operation of dedicated sleep diagnostic centers inside customer healthcare facilities (managed services). Pricing is not publicly disclosed and is contracted on a B2B basis with healthcare providers. The company serves over 300 clinics and hospitals and a referral network of 9,000+ physicians, treating 150,000+ patients per year and performing 49,000+ EEGs in 2025.

The company holds FDA 510(k) clearances (four Class II devices), EU MDR Class IIa CE marking, ISO 13485:2016, and MDSAP certification covering US, Canada, Brazil, Japan, and Australia. Jolt Capital invested €24 million in November 2023 to fund US and broader European expansion and AI deployment, joining existing investors Bpifrance, Dassault Systemes, Idinvest Partners, LBO France, Kurma Partners, Scor, and Innovation Capital. Headquartered in Paris (relocated January 1, 2025), BioSerenity employs 251-500 people and operates with Emmanuel Mougeotte as CEO.

BioSerenity firmographics

Firmographics
Name
BioSerenity
Legal name
BioSerenity Medical Devices Group
Website
https://bioserenity.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
251–500 employees
Short description
BioSerenity is a French medtech company operating an integrated connected-EEG and tele-interpretation platform for hospitals and clinics, combining Neuronaute+ portable EEG recorders, IceCap disposable caps, AI-powered cloud analysis, and proprietary foundation models to serve neurology, sleep medicine, and cardiology diagnostics across 300+ facilities.
Ownership category
akta.pro rank

BioSerenity industry classification

Industry
Product category
Neurological Diagnostic Services
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
akta.pro secondary industries
Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Neurology Telemedicine Platforms (HLALAGAC), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)

Keywords

  • Connected EEG devices
  • Tele-interpretation services
  • Sleep disorder diagnostics
  • Neurology telemedicine
  • Polysomnography interpretation

Where BioSerenity is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

BioSerenity business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Medical Devices (Neuronaute+, IceCap): Sale and supply of connected EEG medical devices (Neuronaute+ portable EEG recorder and IceCap disposable EEG caps) to hospitals, clinics, and healthcare facilities. Devices are FDA and CE certified.
  2. Tele-Interpretation Services (NeuroPhy, Somnophy, Cardiophy): Remote diagnostic interpretation services for EEG (NeuroPhy), polysomnography (Somnophy), and ECG/Holter (Cardiophy). Services include on-demand realization and tele-interpretation by specialist doctors, available 24/7.
  3. Remote Diagnostic Centers: BioSerenity implements sleep diagnostic centers directly within healthcare facilities, providing a comprehensive service that combines equipment, technicians, and medical interpretation.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

BioSerenity product offering

Product offering

Core offering

BioSerenity sells connected EEG medical devices (Neuronaute+ portable recorder and IceCap disposable caps) integrated with a cloud-based AI analysis platform and delivers round-the-clock tele-interpretation services for EEG, polysomnography, and Holter ECG to hospitals, clinics, and sleep medicine centers. The company combines hardware, AI software, and on-demand specialist physician interpretation to enable brain monitoring and remote diagnostics across neurology, sleep medicine, and cardiology.

Product overview

BioSerenity is an integrated neuroscience platform comprising medical devices and telemedicine services. The core product portfolio includes Neuronaute+ (portable connected EEG recorder) and IceCap (disposable EEG caps) working together as a complete EEG system, supported by the Bioserenity Cloud platform for data storage and AI analysis. The service offerings include Neurophy (on-demand EEG tele-interpretation), Somnophy (polysomnography interpretation), and Cardiophy (Holter ECG interpretation), all delivered through a network of specialist physicians and technicians. B-Link and BLINK Mobile App are complementary accessories enabling video synchronization and mobile session configuration. The platform enhances neurological diagnostics and sleep disorder treatment through AI-powered pre-analysis of electrophysiological signals.

Differentiator

Problem solved

Functional benefit

Brands

  • Neurophy: On-demand EEG realization and tele-interpretation service for hospitals and clinics.
  • Somnophy
  • Cardiophy
  • Neuronaute+
  • IceCap
  • BIOSerenity Connect
  • B-Link
  • Neuronaute EEG Platform

Products and services

  • Neuronaute+ Portable and connected EEG recorder that enables electroencephalographic examinations at the patient's bedside, at home, or in complex hospital environments (ICU, pediatrics, operating rooms). Compact, battery-powered, lightweight device with interchangeable extensions compatible with IceCap and standard EEG caps. Features AI pre-analysis to screen signal abnormalities. FDA-cleared Class II (K231366) and CE-marked Class IIa medical device.
  • IceCap Extra-light disposable EEG cap (less than 10 grams) available in 5 sizes from neonate to adult, set up in 10 minutes for hospital or home exams. Supports recordings up to 72 hours. Compatible with standard touchproof EEG acquisition systems via Neuronaute Touchproof adapters. CE-marked Class I and FDA-cleared Class II medical device.
  • Bioserenity Cloud (Connect) Web-based information system that receives EEG and video signals from the Neuronaute recorder and B-Link app through paired Wi-Fi connection. Enables long-term storage, signal integration, AI pre-analysis for abnormality screening, and remote analysis by specialists. Class IIa medical device.
  • Neurophy On-demand EEG realization and tele-interpretation service providing 24/7 technician deployment with Neuronaute+ and IceCap equipment to hospitals, clinics, and private practices. Average tele-interpretation time under 2 hours for routine EEG (maximum 3 hours) and 30 minutes for emergencies. Over 300 partner hospitals and 950+ weekly examinations performed in 2025.
  • Somnophy Remote polysomnography (PSG) interpretation platform providing realization and interpretation services for sleep studies. Network of sleep medicine physicians and technicians scoring PSG recordings from children to adults, 7 days a week, with 6-hour interpretation turnaround. 7 diagnostic sleep centers in France.
  • Cardiophy Remote Holter ECG interpretation service offering ECG monitoring with up to 14-day battery life, wireless 3-lead patch, and semi-waterproof design. Includes interpretation by cardiologist/electrophysiologist team. Service available with 24/7 technical support.
  • B-Link Mobile Application Android application that transforms a smartphone into a video monitoring and recording station synchronized with EEG recordings. Sends video data to Bioserenity Cloud for remote specialist analysis. Class IIa medical device accessory.

Quantifiable outcome

  • 150,000+ patients treated yearly through BioSerenity's diagnostic services
  • +6 more outcomes

Companies that use BioSerenity

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

BioSerenity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

BioSerenity partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor.

  • APTE AssociationminorStrategic or Co-development PartnerAPTE Association is part of BioSerenity's Somnophy network of technicians holding Sleep Medicine degrees, providing pre-scoring services for polysomnography recordings.
  • OpossommminorStrategic or Co-development PartnerOpossomm is part of BioSerenity's Somnophy network of technicians holding Sleep Medicine degrees, providing pre-scoring services for polysomnography recordings.
  • Circle of Sleep SocietyminorStrategic or Co-development PartnerCircle of Sleep Society is part of BioSerenity's Somnophy network of technicians holding Sleep Medicine degrees, providing pre-scoring services for polysomnography recordings.
  • Ensodata, Inc.minorStrategic or Co-development PartnerBioSerenity collaborated with Ensodata to achieve a first-of-kind FDA clearance for interoperable AI analysis of PPG (photoplethysmography). Testimonial from Chris Fernandez, Executive Chairman and Chief Research Officer at Ensodata, highlights the successful collaboration.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

BioSerenity competitors and assessment

Company assessment

Direct peers

  • Brain Products GmbH: Germany-based manufacturer of research- and clinical-grade EEG hardware and caps. Directly competes with Neuronaute+ and IceCap as a European EEG device specialist.
  • Compumedics Limited: Australia-based manufacturer of clinical EEG, PSG, and sleep-diagnostic devices with cloud analysis software. Directly comparable to BioSerenity's hardware-plus-software stack for neurology and sleep labs worldwide.
  • Ceribell Inc: AI-powered point-of-care EEG system with cloud-based interpretation for hospital and ICU use. Closest analog to BioSerenity's combination of bedside EEG hardware + cloud AI + remote specialist interpretation.
  • Nox Medical: Icelandic sleep-diagnostics company offering PSG systems and cloud software for sleep labs. Closely comparable to BioSerenity's Somnophy PSG interpretation offering and overall sleep franchise.
  • EnsoData: AI sleep-scoring and clinical diagnostics platform with FDA-cleared interoperable PSG analysis. BioSerenity has cited EnsoData as a collaborator on FDA-cleared PPG AI analysis — directly comparable on the AI-interpretation layer.

Broad incumbents

  • Natus Medical Incorporated: Large neurology-diagnostics portfolio company offering EEG, PSG, EMG, and ICU monitoring devices globally. A broader incumbent that competes with BioSerenity's Neuronaute+ and IceCap in hospital neurology and sleep labs.
  • Masimo Corporation: Large patient-monitoring company whose SedLine EEG-processed brain-monitoring product overlaps with BioSerenity's hospital EEG franchise. A broad incumbent with global hospital-channel reach.
  • Koninklijke Philips N.V. Global health-tech incumbent with sleep & respiratory (Philips Respironics) and clinical patient-monitoring portfolios. Overlaps with BioSerenity's Somnophy sleep-diagnostic and Cardiophy ECG services in hospital and home settings.

Emerging players

  • Wave Neuroscience: EEG-based personalized neurostimulation and brain-mapping platform. Comparable as an emerging EEG + AI + clinical-interpretation stack, though focused on therapy rather than diagnostics.
  • iMediSync: AI-driven EEG diagnostic platform for early detection of neurological conditions (e.g., Alzheimer's, depression). Comparable to BioSerenity's foundation-model strategy of using EEG for disease prediction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BioSerenity social profiles

Digital presence

BioSerenity compliance and trust

Trust signal

Compliance4 records

BioSerenity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSerenity leadership team

Management profile

Number of profiles

Profiles10 records

BioSerenity funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSerenity M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSerenity

What does BioSerenity do?

BioSerenity sells connected EEG medical devices (Neuronaute+ portable recorder and IceCap disposable caps) integrated with a cloud-based AI analysis platform and delivers round-the-clock tele-interpretation services for EEG, polysomnography, and Holter ECG to hospitals, clinics, and sleep medicine centers. The company combines hardware, AI software, and on-demand specialist physician interpretation to enable brain monitoring and remote diagnostics across neurology, sleep medicine, and cardiology.

Is BioSerenity a public or private company?

BioSerenity is a private company. It is classified as private equity controlled and is currently operating.

When was BioSerenity founded?

BioSerenity was founded in 2014. It employs 251 to 500 people.

Where is BioSerenity based?

BioSerenity is headquartered in Paris, France, in the Europe region.

How does BioSerenity make money?

Three revenue lines are on record. Medical Devices (Neuronaute+, IceCap) is the primary driver. The others are tele-Interpretation Services (NeuroPhy, Somnophy, Cardiophy) and remote Diagnostic Centers.

Who are BioSerenity's main competitors?

Direct peers on record are Brain Products GmbH, Compumedics Limited, Ceribell Inc, Nox Medical and EnsoData. Broad incumbents are Natus Medical Incorporated, Masimo Corporation and Koninklijke Philips N.V.. Emerging players are Wave Neuroscience and iMediSync.

Does BioSerenity have an API?

No public API is recorded for BioSerenity.

What industry is BioSerenity in?

BioSerenity's product category is Neurological Diagnostic Services. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioserenityJolt Capital invests in BIOSerenity, a leader in neurological diagnostics and sleep disordersJolt Capital has invested €24 million in BIOSerenity to support its international expansion and the deployment of artificial intelligence in telemedicine. Concurrently, Vincent Marcel was appointed as CEO of BIOSerenity to strengthen the management team. This funding aims to accelerate development in key markets including France, the United States, and Europe.Web3OclockBioSerenity Secures €24M Funding to Boost AI DiagnosesFrench medtech startup BioSerenity has secured €24 million in funding from Jolt Capital to accelerate its international expansion and enhance AI-driven diagnostic technologies. The investment will support growth in existing markets such as France and the United States while targeting further development across Europe. Additionally, BioSerenity plans to use the funds to strengthen its management team and deploy advanced medical AI for detecting digital biomarkers.Medical BuyerJolt Capital invests €24 million in BioSerenityJolt Capital has invested €24 million in BioSerenity to accelerate its international expansion, particularly in Europe and the United States. The funding will be utilized to enhance BioSerenity's AI capabilities for medical diagnoses and strengthen its management team.Jolt CapitalJolt Capital invests €24M in BioSerenity — Jolt CapitalJolt Capital has invested €24 million in BioSerenity to accelerate international expansion and the deployment of artificial intelligence in telemedicine. Concurrently, Vincent Marcel was appointed as the new CEO of BioSerenity to lead its growth strategy in France, the United States, and Europe.CoveragerSCOR makes follow-on investment in BioSerenitySCOR has made a follow-on investment in BioSerenity, a French medical technology company specializing in remote diagnostics and IoMT for neurology, sleep medicine, and cardiology. This strategic move aims to simplify medical underwriting for life insurance by leveraging BioSerenity's at-home diagnostic tools, such as the Cardiophy Check-up, to make insurance more accessible and improve policyholder health outcomes.PR NewswireWeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ CommercializationBioSerenity has acquired the global distribution rights to Cardioskin™, a digital ECG medical device co-developed by WeHealth™ Digital Medicine and Servier Group. This agreement allows BioSerenity to integrate the device into its Cardiophy™ remote cardiology service for deployment across Europe, Asia, and North America. In exchange, BioSerenity will provide Servier with upfront payments and variable fees on future net sales.PR NewswireBioSerenity, Leader in Healthcare as a Service (HaaS), Develops Virtual Clinics Providing Greater Access to Care for People with EpilepsyBioSerenity announced publication of an article in Epilepsy & Behavior describing its deployment of virtual clinics providing remote electroencephalogram (EEG) diagnostic services for people with epilepsy. The company has developed these telehealth services for the Caribbean, Latin America, and rural areas of North America, shifting diagnostics from hospitals directly to patients to address gaps in neurology specialist availability. Medical experts quoted in the article note that virtual outpatient care will expand rapidly post-COVID-19, with the potential to improve epilepsy care access in underserved regions worldwide.PR NewswireBioSerenity, Leader in Healthcare as a Service (HaaS), Helps Advance Understanding of COVID-19 Neurological ImpactBioSerenity collaborated with hospitals in Paris, France to perform remote EEG tests on critically ill COVID-19 patients, leading to the discovery of frontal brain abnormalities associated with the virus. The findings were published in Annals of Neurology and suggest that EEGs should be part of the diagnostic assessment for patients presenting with unexplained mental status changes. This collaboration highlights BioSerenity's capability to provide 24/7 hospital assistance during health crises.FinSMEsBioSerenity Raises €65M in Series B Equity FundingBioSerenity, a Paris-based developer of personalized patient care solutions, raised €65M in Series B equity funding led by Dassault Systèmes, which invested €50M. The company will use the funds to accelerate sensor-equipped wearables and telehealth for cardiology, neurology, and sleep disorders, and to expand internationally.GlobeNewswireDassault Systèmes: Dassault Systèmes Continues to Demonstrate Its Commitment to Life Sciences for Patient Experience by Investing in BioSerenityDassault Systèmes led a €65 million Series B financing round for BioSerenity, a startup developing sensor-equipped wearables and telehealth for chronic disease monitoring. The funds will accelerate development in cardiology, neurology, and sleep disorders, and expand international growth and telemedicine solutions.